Pneumology Meets Oto-Rhino-Laryngology: A Discussion of Type 2 Inflammation in Airway Diseases
Present evidence from clinical trials and real-world experience to demonstrate the safety and efficacy of Dupilumab, a biologic targeting the key and central cytokines of Type 2 inflammation, in both upper and lower airway diseases.
![BR0095028_D0534766_CRSwNP Omnichannel Guidance & Segmentation_V2](/.imaging/webp/sanofi-templates/w1080-16-9/dam/campus-sanofi-kw/Article-Images/images/image-(39).png/jcr:content/image%20(39).png)
BR0095028_D0534766_CRSwNP Omnichannel Guidance & Segmentation_V2
Related articles
MAT-BH-2300373/V1/JUNE 2023